JPWO2019173180A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019173180A5 JPWO2019173180A5 JP2020570400A JP2020570400A JPWO2019173180A5 JP WO2019173180 A5 JPWO2019173180 A5 JP WO2019173180A5 JP 2020570400 A JP2020570400 A JP 2020570400A JP 2020570400 A JP2020570400 A JP 2020570400A JP WO2019173180 A5 JPWO2019173180 A5 JP WO2019173180A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- bedtime
- tasimelteon
- sleep
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PTOIAAWZLUQTIO-GXFFZTMASA-N Tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 claims description 24
- 229960000660 tasimelteon Drugs 0.000 claims description 22
- 230000004622 sleep time Effects 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 5
- 230000037007 arousal Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 206010009191 Circadian rhythm sleep disease Diseases 0.000 claims description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 2
- 206010041349 Somnolence Diseases 0.000 claims description 2
- 230000004620 sleep latency Effects 0.000 claims description 2
- 230000002459 sustained Effects 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023212077A JP2024023688A (ja) | 2018-03-04 | 2023-12-15 | タシメルテオンを用いる障害の治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638212P | 2018-03-04 | 2018-03-04 | |
| US62/638,212 | 2018-03-04 | ||
| US201862675687P | 2018-05-23 | 2018-05-23 | |
| US62/675,687 | 2018-05-23 | ||
| PCT/US2019/020491 WO2019173180A1 (fr) | 2018-03-04 | 2019-03-04 | Traitement de troubles avec tasimelteon |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023212077A Division JP2024023688A (ja) | 2018-03-04 | 2023-12-15 | タシメルテオンを用いる障害の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517910A JP2021517910A (ja) | 2021-07-29 |
| JPWO2019173180A5 true JPWO2019173180A5 (fr) | 2022-03-02 |
Family
ID=65818613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570400A Pending JP2021517910A (ja) | 2018-03-04 | 2019-03-04 | タシメルテオンを用いる障害の治療 |
| JP2023212077A Pending JP2024023688A (ja) | 2018-03-04 | 2023-12-15 | タシメルテオンを用いる障害の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023212077A Pending JP2024023688A (ja) | 2018-03-04 | 2023-12-15 | タシメルテオンを用いる障害の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210361611A1 (fr) |
| EP (1) | EP3761974A1 (fr) |
| JP (2) | JP2021517910A (fr) |
| KR (2) | KR20200119296A (fr) |
| CN (1) | CN112074268A (fr) |
| AU (1) | AU2019232702A1 (fr) |
| BR (1) | BR112020017886A2 (fr) |
| CA (1) | CA3092926A1 (fr) |
| MX (1) | MX2020009159A (fr) |
| PH (1) | PH12020500645A1 (fr) |
| RU (1) | RU2020131941A (fr) |
| SG (1) | SG11202007642RA (fr) |
| WO (1) | WO2019173180A1 (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6045513A (ja) * | 1983-05-18 | 1985-03-12 | モナシユ ユニバ−シテイ | 身体行動および機能の日周期の不調を軽減する薬剤 |
| CA2274183C (fr) | 1996-12-10 | 2006-10-24 | Bristol-Myers Squibb Company | Les benzodioxole, benzofuran, dihydrobenzofuran, et benzodioxane: des agents melatonergiques |
| EP2028937B2 (fr) * | 2006-05-22 | 2018-06-27 | Vanda Pharmaceuticals Inc. | Traitement par un agoniste de la mélatonine |
| EP2453891A1 (fr) * | 2009-07-16 | 2012-05-23 | Vanda Pharmaceuticals Inc. | Utilisation d un agoniste de la mélatonine pour le traitement des troubles du sommeil y compris l insomnie primaire |
| BR112014018429A8 (pt) * | 2012-01-26 | 2017-07-11 | Vanda Pharmaceuticals Inc | Método para tratar um paciente que sofre de não-24, e, método para o tratamento crônico de não-24 em uma pessoa que está totalmente cega |
| CA2957588C (fr) * | 2014-09-02 | 2021-08-31 | Vanda Pharmaceuticals Inc. | Tasimelteon pour le traitement du syndrome de smith magenis |
| US11013713B2 (en) * | 2015-12-15 | 2021-05-25 | Vanda Pharmaceuticals Inc. | Method of treatment |
-
2019
- 2019-03-04 CA CA3092926A patent/CA3092926A1/fr active Pending
- 2019-03-04 US US16/977,801 patent/US20210361611A1/en not_active Abandoned
- 2019-03-04 EP EP19712344.1A patent/EP3761974A1/fr active Pending
- 2019-03-04 KR KR1020207026047A patent/KR20200119296A/ko not_active IP Right Cessation
- 2019-03-04 JP JP2020570400A patent/JP2021517910A/ja active Pending
- 2019-03-04 KR KR1020237045331A patent/KR20240007693A/ko active Search and Examination
- 2019-03-04 AU AU2019232702A patent/AU2019232702A1/en active Pending
- 2019-03-04 WO PCT/US2019/020491 patent/WO2019173180A1/fr unknown
- 2019-03-04 BR BR112020017886-1A patent/BR112020017886A2/pt unknown
- 2019-03-04 RU RU2020131941A patent/RU2020131941A/ru unknown
- 2019-03-04 SG SG11202007642RA patent/SG11202007642RA/en unknown
- 2019-03-04 CN CN201980014664.4A patent/CN112074268A/zh active Pending
- 2019-03-04 MX MX2020009159A patent/MX2020009159A/es unknown
-
2020
- 2020-08-26 PH PH12020500645A patent/PH12020500645A1/en unknown
-
2023
- 2023-12-15 JP JP2023212077A patent/JP2024023688A/ja active Pending
-
2024
- 2024-03-21 US US18/611,987 patent/US20240226055A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11033543B2 (en) | Methods of providing weight loss therapy in patients with major depression | |
| Volovitz et al. | Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes | |
| US20200108029A1 (en) | Methods and systems for treating overweight individuals | |
| JPWO2019173180A5 (fr) | ||
| Imam et al. | Single maintenance and reliever therapy in treatment of asthma exacerbations | |
| EP2900253B1 (fr) | Procédés d'atténuation des symptômes de la sclérose en plaques basés sur des compositions contenant de l'apoaequorine | |
| Bhat et al. | Evaluation of propranolol, flunarizine and divalproex sodium in prophylaxis of migraine | |
| Karal et al. | Drugs and natural products used in COPD | |
| JP2024023688A (ja) | タシメルテオンを用いる障害の治療 | |
| Kiran et al. | AN OPEN-LABELED, MULTICENTRIC, POST-MARKETING SURVEILLANCE (PMS) TO SUBSTANTIATE THE SAFETY AND EFFICACY OF SINAREST SYRUP IN PATIENTS OF COMMON COLD. | |
| Young et al. | A randomised controlled trial of cannabis based medicinal extract in central neuropathic pain due to multiple sclerosis | |
| Teleuca et al. | The prospects of the use of homeopathic medicines sactus with mental disorders | |
| CN104107204A (zh) | 一种治疗脑萎缩及面神经瘫痪的药物组合物 | |
| Nelson | Sublingual immunotherapy for aeroallergens: optimal patient dosing, regimen and duration | |
| Chaplin et al. | Relvar Ellipta: new once‐daily steroid/LABA inhaler | |
| Lorber et al. | Desloratadine is effective at relieving nasal congestion, as demonstrated in three placebo-controlled trials in patients with seasonal allergic rhinitis | |
| Dirksen et al. | Is phenobarbital effective in treating alcohol withdrawal? | |
| Davis | Why use sedative antihistamines at all?: allergies | |
| Pawasauskas et al. | (422) Pain-related characteristics of inpatient admissions for acute pancreatitis: a retrospective study | |
| Cheruvu et al. | (421) Comparison of subjective drug effects of orally administered MNK-155 extended-release hydrocodone bitartrate/acetaminophen (HB/APAP ER) tablets versus immediate-release hydrocodone bitartrate/acetaminophen tablets in recreational users of prescription opioids | |
| Elliott et al. | Pharmacology Update-Suvorexant Tablets (Belsomra®) | |
| Lotvall | Inhaled combination therapy with glucocorticoids and long-acting | |
| Krusz | Intradermal botulinum toxin type A, in treating pain syndromes |